Related Experiment Video
Updated: Apr 19, 2026
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Neuron Loss and Behavioral Deficits in the TBA42 Mouse Model Expressing N-Truncated Pyroglutamate Amyloid-β3-42
Julius N Meißner1, Yvonne Bouter1, Thomas A Bayer1
1Division of Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University Medicine Göttingen, Georg-August-University of Göttingen, Germany.
Abstract:
Pyroglutamate-modified amyloid-β (Aβ) at amino acid position three (Aβ(pE3-42)) is gaining considerable attention as a potential key player in the pathogenesis of Alzheimer's disease (AD). Aβ(pE3-42) is abundant in AD brain and has a high aggregation propensity, stability, and cellular toxicity. The aim of the present work was to study the effect of Aβ(pE3-42) expression on neuron loss and associated behavioral deficits using the TBA42 transgenic mouse model. Expression of pyroglutamate Aβ(3-42) triggers hippocampal CA1 neuron loss and behavioral deficits in the TBA42 mouse model. Mice elicited significant neuron death (-35% at the age of 12 months), deficits in the spatial reference memory, working memory, loss of anxiety, and severe motor deficits in an age-dependent manner. These results support a major pathological function of pyroglutamate Aβ in AD.
Insights
Pyroglutamate amyloid-beta (Aβ(pE3-42)) drives Alzheimer's disease (AD) pathology, causing significant neuron loss and memory deficits in mice. This highlights Aβ(pE3-42) as a key factor in AD pathogenesis.
Area of Science:
- Neuroscience
- Pathology
- Alzheimer's Disease Research
Background:
- Pyroglutamate-modified amyloid-beta (Aβ(pE3-42)) is increasingly recognized for its role in Alzheimer's disease (AD) pathogenesis.
- Aβ(pE3-42) is notably abundant in AD brains and exhibits high aggregation propensity, stability, and cellular toxicity.
Purpose of the Study:
- To investigate the impact of Aβ(pE3-42) expression on neuronal loss and behavioral impairments.
- To utilize the TBA42 transgenic mouse model for studying Alzheimer's disease mechanisms.
Main Methods:
- Generation and analysis of the TBA42 transgenic mouse model expressing pyroglutamate Aβ(3-42).
- Assessment of hippocampal CA1 neuron survival, spatial reference and working memory, anxiety levels, and motor function in a time-dependent manner.
Main Results:
- Expression of pyroglutamate Aβ(3-42) led to significant hippocampal CA1 neuron death (-35% by 12 months of age).
- TBA42 mice exhibited age-dependent deficits in spatial memory, working memory, reduced anxiety, and severe motor impairments.
Conclusions:
- Pyroglutamate Aβ(pE3-42) expression directly triggers substantial neuron loss and cognitive/motor deficits in the TBA42 mouse model.
- These findings strongly support a significant pathological role for pyroglutamate Aβ in Alzheimer's disease progression.
